M&A Deal Summary |
|
|---|---|
| Date | 2025-07-31 |
| Target | Regis Technologies |
| Sector | Life Science |
| Buyer(s) | Esteve Pharmaceuticals S.A. |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1929 |
| Sector | Life Science |
| Employees | 2,300 |
| Revenue | 758M EUR (2018) |
Esteve Pharmaceuticals, S.A. is a global pharmaceutical company offers solutions in the pharmaceutical segment, mainly in Spain with a broad and highly innovative product portfolio and as a global Contract Manufacturing Organization (CMO). ESTEVE is at present advancing in its transformation journey to become an international proprietary specialty pharmaceutical company.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Illinois M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-08 |
Riemser Arzneimittel AG
Greifswald - Insel Riems, Germany Riemser Arzneimittel AG is a pharmaceutical company focuses on its activities is mainly due to the distribution and life cycle management of pharmaceuticals in therapeutic niche areas with high unmet medical needs. Riemser product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary axillary hyperhidrosis. |
Buy | - |
